Choline as a Biomarker for Cell Proliferation: Do the Results From Proton MR Spectroscopy Show Difference Between HER2/neu Positive and Negative Breast Cancers?

International Journal of Cancer - United States
doi 10.1002/ijc.23552
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Do Multifocal or Multicentric pT1a Node-Negative HER2+ Breast Cancers Get Benefit From Systemic Treatment?

Breast Cancer Research and Treatment
Cancer ResearchOncology
2019English

A Phenotypic and Mechanistic Perspective on Heterogeneity of HER2-positive Breast Cancers

Molecular and Cellular Oncology
Cancer ResearchMolecular Medicine
2016English

Positive Response to Neoadjuvant Cyclophosphamide and Doxorubicin in Topoisomerase II Nonamplified/Her2/Neu Negative/Polysomy 17 Absent Breast Cancer Patients

Cancer Management and Research
Oncology
2010English

Functional Implications of Structural Predictions for Alternative Splice Proteins Expressed in Her2/Neu–Induced Breast Cancers

Journal of Proteome Research
BiochemistryChemistry
2011English

miR-17 as a Diagnostic Biomarker Regulates Cell Proliferation in Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2017English

MiR-190b, the Highest Up-Regulated miRNA in ERα-positive Compared to ERα-negative Breast Tumors, a New Biomarker in Breast Cancers?

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

Identification of New miRNA Biomarkers Associated With HER2-positive Breast Cancers

Oncoscience
Cancer ResearchOncology
2015English

ZW25 Active in HER2-positive Cancers

Cancer Discovery
Oncology
2018English

Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer

Journal of Molecular Biomarkers & Diagnosis
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy